Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
TTLC 2020
Targeted Therapies in Lung Cancer 2020
Access to all slides from presentations that occur during the IASLC 2020 Targeted Therapies of Lung Cancer Meeting in Santa Monica, CA
Presentation Date(s):- February 19 – 22, 2020
- Total Presentations: 230
-
+
OS - Opening Ceremony / Welcome Reception
- Type: General Session
- Track:
- Presentations: 5
- Slides Available
- Coordinates: 2/19/2020, 18:00 - 20:05,
-
+
CEO Welcome
19:00 - 19:05 | Author(s): Dave Mesko
- Abstract
No abstract available for this presentation
-
+
President's Welcome
19:05 - 19:10 | Author(s): Tetsuya Mitsudomi
- Abstract
No abstract available for this presentation
-
+
Scientific Talk 1 : What Contributed to the Recent Sharp Decline in Lung Cancer Mortality? (Slides Available)
19:10 - 19:30 | Author(s): Helmneh Sineshaw
- Abstract
No abstract available for this presentation
-
+
Scientific Talk 2: Drug Approvals Past, Present, Future (Slides Available)
19:30 - 19:50 | Author(s): Harpreet Singh
- Abstract
No abstract available for this presentation
-
+
20 Years of Targeted Therapies: Evolving Targets and Innovative Therapies
19:50 - 20:05 | Author(s): Paul A. Bunn Jr.
- Abstract
No abstract available for this presentation
-
+
S01 - EGFR TKI's
- Type: General Session
- Track:
- Presentations: 24
- Slides Available
- Coordinates: 2/20/2020, 07:30 - 09:45,
-
+
Science (Slides Available)
07:30 - 07:40 | Author(s): Pasi Janne
- Abstract
No abstract available for this presentation
-
+
Zn-e4 (Slides Available)
07:40 - 07:45 | Author(s): Karen Reckamp
- Abstract
No abstract available for this presentation
-
+
HS10296 (Slides Available)
07:45 - 07:50 | Author(s): Lyudmila Bazhenova
- Abstract
No abstract available for this presentation
-
+
Rezivertinib (BPI-7711) (Slides Available)
07:50 - 07:55 | Author(s): Sai-Hong Ou
- Abstract
No abstract available for this presentation
-
+
Lazertinib (Slides Available)
07:55 - 08:00 | Author(s): Keunchil Park
- Abstract
No abstract available for this presentation
-
+
Tak788 (Slides Available)
08:00 - 08:05 | Author(s): Howard West
- Abstract
No abstract available for this presentation
-
+
Poziotinib (Slides Available)
08:05 - 08:10 | Author(s): Jacqulyne Robichaux
- Abstract
No abstract available for this presentation
-
+
Osimertinib (Slides Available)
08:10 - 08:15 | Author(s): Lecia Sequist
- Abstract
No abstract available for this presentation
-
+
Tarloxitinib (Slides Available)
08:15 - 08:20 | Author(s): Viola Zhu
- Abstract
No abstract available for this presentation
-
+
Pyrotinib (Slides Available)
08:20 - 08:25 | Author(s): George Simon
- Abstract
No abstract available for this presentation
-
+
CLN-081 (TAS6417) (Slides Available)
08:25 - 08:30 | Author(s): Helena Yu
- Abstract
No abstract available for this presentation
-
+
DZD9008 (Slides Available)
08:30 - 08:35 | Author(s): Deborah Doroshow
- Abstract
No abstract available for this presentation
-
+
EGFR + MET (Savolitinib, Tepotinib, Capmatanib) (Slides Available)
08:35 - 08:40 | Author(s): Mark Kris
- Abstract
No abstract available for this presentation
-
+
JNJ61186372 (Slides Available)
08:40 - 08:45 | Author(s): Rachel Sanborn
- Abstract
No abstract available for this presentation
-
+
Olecumab (anti-CD73) (Slides Available)
08:45 - 08:50 | Author(s): Sarah Goldberg
- Abstract
No abstract available for this presentation
-
+
Atezo/bev/CT and other 2vs3 or 4 (Slides Available)
08:50 - 08:55 | Author(s): Mark Socinski
- Abstract
No abstract available for this presentation
-
+
Afatinib + Necitumumab (Slides Available)
08:55 - 09:00 | Author(s): Sukhmani Padda
- Abstract
No abstract available for this presentation
-
+
Dasatinib (Slides Available)
09:00 - 09:05 | Author(s): Hatim Husain
- Abstract
No abstract available for this presentation
-
+
Navitoclax (Slides Available)
09:05 - 09:10 | Author(s): Elaine Shum
- Abstract
No abstract available for this presentation
-
+
Sepanisertib (Slides Available)
09:10 - 09:15 | Author(s): Penelope Bradbury
- Abstract
No abstract available for this presentation
-
+
Alisertib
09:15 - 09:20 | Author(s): Trever Bivona
- Abstract
No abstract available for this presentation
-
+
CB 839 Telaglenastat (Slides Available)
09:20 - 09:25 | Author(s): Greg Otterson
- Abstract
No abstract available for this presentation
-
+
Platinum doublet (Slides Available)
09:25 - 09:30 | Author(s): Ronald Natale
- Abstract
No abstract available for this presentation
-
+
Temozolomide + TKI for recurrent brain metastases (Slides Available)
09:30 - 09:35 | Author(s): Jose Pacheco
- Abstract
No abstract available for this presentation
-
+
D01 - What do you give to patients with EGFR Mutation in the first line?
- Type: General Session
- Track:
- Presentations: 3
- Slides Available
- Coordinates: 2/20/2020, 09:45 - 10:00,
-
+
TKI + VEGF (Slides Available)
09:45 - 09:50 | Author(s): Howard West
- Abstract
No abstract available for this presentation
-
+
Chemo plus TKI (Slides Available)
09:50 - 09:55 | Presenter: Philip Bonomi
- Abstract
No abstract available for this presentation
-
+
TKI alone (Slides Available)
09:55 - 10:00 | Presenter: Mark Kris
- Abstract
No abstract available for this presentation
-
+
S02 - Small Cell Lung Cancer
- Type: General Session
- Track:
- Presentations: 23
- Slides Available
- Coordinates: 2/20/2020, 10:20 - 12:30,
-
+
Science (Slides Available)
10:20 - 10:30 | Author(s): Charles Rudin
- Abstract
No abstract available for this presentation
-
+
Nivolumab Combinations
10:30 - 10:35 | Author(s): Ticiana Leal
- Abstract
No abstract available for this presentation
-
+
Durvalumab +/- Chemo (Slides Available)
10:35 - 10:40 | Author(s): Jonathan Goldman
- Abstract
No abstract available for this presentation
-
+
Atezolizumab +/- Chemo (Slides Available)
10:40 - 10:45 | Author(s): Stephen Liu
- Abstract
No abstract available for this presentation
-
+
Pembrolizumab +/- Chemo (Slides Available)
10:45 - 10:50 | Author(s): Victoria Lai
- Abstract
No abstract available for this presentation
-
+
Nivolumab + temozolomide (Slides Available)
10:50 - 10:55 | Author(s): Dwight Owen
- Abstract
No abstract available for this presentation
-
+
Dinutuximab (Slides Available)
10:55 - 11:00 | Author(s): Martin Edelman
- Abstract
No abstract available for this presentation
-
+
Lurbinectidin (Slides Available)
11:00 - 11:05 | Author(s): William Petty
- Abstract
No abstract available for this presentation
-
+
PARP Inhibitors (Slides Available)
11:05 - 11:10 | Author(s): Ben Drapkin
- Abstract
No abstract available for this presentation
-
+
Olaparib + temozolomide (Slides Available)
11:10 - 11:15 | Author(s): Anna Farago
- Abstract
No abstract available for this presentation
-
+
AMG 757 (DLL3) + AMG 119 (DLL3) (CAR-T) (Slides Available)
11:15 - 11:20 | Author(s): Hossein Borghaei
- Abstract
No abstract available for this presentation
-
+
GD-2 CAR
11:20 - 11:25 | Author(s): Jared Weiss
- Abstract
No abstract available for this presentation
-
+
Irinotecan (onidyve) (Slides Available)
11:25 - 11:30 | Author(s): Paul A. Bunn Jr.
- Abstract
No abstract available for this presentation
-
+
PAX5 (BSAP) (Slides Available)
11:30 - 11:35 | Author(s): Ravi Salgia
- Abstract
No abstract available for this presentation
-
+
INCB05987 +/- IO (next to IO at top) (Slides Available)
11:35 - 11:40 | Author(s): Young Kwang Chae
- Abstract
No abstract available for this presentation
-
+
Somatostatin Receptor (Slides Available)
11:40 - 11:45 | Author(s): Jonathan Lehman
- Abstract
No abstract available for this presentation
-
+
AZD2811 + other Aurora Kinase Inhibitors (Slides Available)
11:45 - 11:50 | Author(s): Carl Gay
- Abstract
No abstract available for this presentation
-
+
RRx-001 (Slides Available)
11:50 - 11:55 | Author(s): Daniel Morgensztern
- Abstract
No abstract available for this presentation
-
+
Chemo-RT (Slides Available)
11:55 - 12:00 | Author(s): Roy Decker
- Abstract
No abstract available for this presentation
-
+
Chemo + IO + RT (Slides Available)
12:00 - 12:05 | Author(s): Helen Ross
- Abstract
No abstract available for this presentation
-
+
Role of PCI in era of chemo IO (Slides Available)
12:05 - 12:10 | Author(s): Kristin Higgins
- Abstract
No abstract available for this presentation
-
+
Cell free DNA (Slides Available)
12:10 - 12:15 | Author(s): Wade Iams
- Abstract
No abstract available for this presentation
-
+
TAXOL + APG1252 (BCLXL) + (Slides Available)
12:15 - 12:20 | Author(s): Gregory Kalemkerian
- Abstract
No abstract available for this presentation
-
+
S03 - Immune Checkpoint Inhibitors
- Type: General Session
- Track:
- Presentations: 15
- Slides Available
- Coordinates: 2/20/2020, 13:30 - 15:00,
-
+
Science (Slides Available)
13:30 - 13:40 | Author(s): Roy Herbst
- Abstract
No abstract available for this presentation
-
+
Long term follow up single agent (Slides Available)
13:40 - 13:45 | Author(s): Neal Ready
- Abstract
No abstract available for this presentation
-
+
Long term follow up chemo-combo (Slides Available)
13:45 - 13:50 | Author(s): David Ettinger
- Abstract
No abstract available for this presentation
-
+
Sensitivity and resistance STK11 (Slides Available)
13:50 - 13:55 | Author(s): Ferdinandos Skoulidis
- Abstract
No abstract available for this presentation
-
+
Sensitivity and resistance HLA microglobulin (Slides Available)
13:55 - 14:00 | Author(s): Katerina Politi
- Abstract
No abstract available for this presentation
-
+
Optimal duration of therapy (Slides Available)
14:00 - 14:05 | Author(s): David Spigel
- Abstract
No abstract available for this presentation
-
+
Optimal IO endpoints
14:05 - 14:10 | Author(s): Yu Shyr
- Abstract
No abstract available for this presentation
-
+
ATL001 (Slides Available)
14:10 - 14:15 | Author(s): Rosalyn Juergens
- Abstract
No abstract available for this presentation
-
+
ADXS 503 (Slides Available)
14:15 - 14:20 | Author(s): Jennifer Carlisle
- Abstract
No abstract available for this presentation
-
+
GRN 1201 (Slides Available)
14:20 - 14:25 | Author(s): Jyoti Patel
- Abstract
No abstract available for this presentation
-
+
M7824 (Slides Available)
14:25 - 14:30 | Author(s): Leora Horn
- Abstract
No abstract available for this presentation
-
+
KN046 (PDL1-CTLA4 bispecific) (Slides Available)
14:30 - 14:35 | Author(s): Vamsidhar Velcheti
- Abstract
No abstract available for this presentation
-
+
PBF 1129 (Slides Available)
14:35 - 14:40 | Author(s): Dwight Owen
- Abstract
No abstract available for this presentation
-
+
CXCL21 Dendritic Vaccine
14:40 - 14:45 | Author(s): Aaron Lisberg
- Abstract
No abstract available for this presentation
-
+
Neo-PV-01 (Slides Available)
14:45 - 14:50 | Author(s): Kathryn Arbour
- Abstract
No abstract available for this presentation
-
+
D02 - Optimal therapy for stage 4 NSCLC patient with low PD-L1 expression (1-49%)
- Type: General Session
- Track:
- Presentations: 3
- Slides Available
- Coordinates: 2/20/2020, 15:20 - 15:35,
-
+
Chemo + PD-1 inhibition (Slides Available)
15:20 - 15:25 | Author(s): Karen Reckamp
- Abstract
No abstract available for this presentation
-
+
Ipi plus Nivo
15:25 - 15:30 | Author(s): Matthew Hellman
- Abstract
No abstract available for this presentation
-
+
PD-1 Inhibition
15:30 - 15:35 | Author(s): Lawrence Einhorn
- Abstract
No abstract available for this presentation
-
+
S04 - Biomarker Panel
- Type: General Session
- Track:
- Presentations: 9
- Slides Available
- Coordinates: 2/20/2020, 15:35 - 16:30,
-
+
IHC/Neoadjuvant (Slides Available)
15:35 - 15:40 | Author(s): Ignacio Wistuba
- Abstract
No abstract available for this presentation
-
+
Multiplex (Slides Available)
15:40 - 15:45 | Author(s): Kurt Schalper
- Abstract
No abstract available for this presentation
-
+
Next Generation Diagnostics for Lung Cancer; Beyond IHC and NGS (Slides Available)
15:45 - 15:50 | Author(s): David Rimm
- Abstract
No abstract available for this presentation
-
+
Tissue and the issue (blueprint) (Slides Available)
15:50 - 15:55 | Author(s): Fred Hirsch
- Abstract
No abstract available for this presentation
-
+
ctDNA (Slides Available)
15:55 - 16:00 | Author(s): Max Diehn
- Abstract
No abstract available for this presentation
-
+
TMB Tissue (Slides Available)
16:00 - 16:05 | Author(s): Hossein Borghaei
- Abstract
No abstract available for this presentation
-
+
TMB Blood (Slides Available)
16:05 - 16:10 | Author(s): David R. Gandara
- Abstract
No abstract available for this presentation
-
+
RT + IO (Slides Available)
16:10 - 16:15 | Author(s): Andrea Bezjak
- Abstract
No abstract available for this presentation
-
+
WIN Consortium (Slides Available)
16:15 - 16:20 | Author(s): Amir Onn
- Abstract
No abstract available for this presentation
-
+
S05 - KRAS/BRAF
- Type: General Session
- Track:
- Presentations: 13
- Slides Available
- Coordinates: 2/20/2020, 16:30 - 17:55,
-
+
Science (Slides Available)
16:30 - 16:40 | Author(s): Gregory Riely
- Abstract
No abstract available for this presentation
-
+
AMG 510 (Slides Available)
16:40 - 16:45 | Author(s): Ramaswamy Govindan
- Abstract
No abstract available for this presentation
-
+
MRTX849 (KRAS 9G12C) (Slides Available)
16:45 - 16:50 | Author(s): Pasi J
- Abstract
No abstract available for this presentation
-
+
Binimetinib (MEK1/2), MEK162 (Binimetinib + Erlotinib) (Slides Available)
16:50 - 17:00 | Author(s): Natasha Leighl
- Abstract
No abstract available for this presentation
-
+
ROS126766 (BRAF, MEK1/2) (Slides Available)
17:00 - 17:05 | Author(s): Jose Pacheco
- Abstract
No abstract available for this presentation
-
+
LXH254+/-LTT (Pan-RAF) (Slides Available)
17:05 - 17:10 | Author(s): Ibiayi Dagogo-Jack
- Abstract
No abstract available for this presentation
-
+
TAK 580 (Non-V600E) (Pan-RAF) (Slides Available)
17:10 - 17:15 | Author(s): Glenwood Goss
- Abstract
No abstract available for this presentation
-
+
Regorafenib + MTX (Multi-TKI)
17:15 - 17:20 | Author(s): Sukhmani Padda
- Abstract
No abstract available for this presentation
-
+
SHP2 Inhibitor RMC-4630 (Slides Available)
17:20 - 17:25 | Author(s): Caroline McCoach
- Abstract
No abstract available for this presentation
-
+
LY3214966 (Slides Available)
17:25 - 17:30 | Author(s): Alex Adjei
- Abstract
No abstract available for this presentation
-
+
Palbociclib + PDO325901 (CDK 4,6 + MEK) (Slides Available)
17:30 - 17:35 | Author(s): Karen Kelly
- Abstract
No abstract available for this presentation
-
+
BVD-523 (ERK1/2) (Slides Available)
17:35 - 17:40 | Author(s): Bob Li
- Abstract
No abstract available for this presentation
-
+
ASN 007 (Slides Available)
17:40 - 17:45 | Author(s): Michael Cheng
- Abstract
No abstract available for this presentation
-
+
S06 - Surgically Resectable NSCLC
- Type: General Session
- Track:
- Presentations: 10
- Slides Available
- Coordinates: 2/21/2020, 07:30 - 08:20,
-
+
Neoadjuvant IO (Nivo, Atezo, Sintilimab) (Slides Available)
07:30 - 07:35 | Author(s): David Carbone
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant nivo + ipi (Slides Available)
07:35 - 07:40 | Author(s): Tina Cascone
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant IO + Chemotherapy (Slides Available)
07:40 - 07:45 | Author(s): Catherine Shu
- Abstract
No abstract available for this presentation
-
+
Adjuvant IO + Chemotherapy (Slides Available)
07:45 - 07:50 | Presenter: Greg Durm
- Abstract
No abstract available for this presentation
-
+
Adjuvant Checkpoint Inhibitors (Slides Available)
07:50 - 07:55 | Author(s): Heather Wakelee
- Abstract
No abstract available for this presentation
-
+
Canakinumab (Slides Available)
07:55 - 08:00 | Author(s): Jay Lee
- Abstract
No abstract available for this presentation
-
+
Crizotinib (Slides Available)
08:00 - 08:05 | Author(s): David Gerber
- Abstract
No abstract available for this presentation
-
+
Osimertinib (Slides Available)
08:05 - 08:10 | Author(s): Colin Blakely
- Abstract
No abstract available for this presentation
-
+
LCMC4
08:10 - 08:15 | Author(s): Jamie Chaft
- Abstract
No abstract available for this presentation
-
+
IO + PCV in ctDNA Positive Adjuvant Post Resection (Slides Available)
08:15 - 08:20 | Author(s): Ross Camidge
- Abstract
No abstract available for this presentation
-
+
D03 - Should IO be given before or after surgery for resectable NSCLC?
- Type: General Session
- Track:
- Presentations: 2
- Slides Available
- Coordinates: 2/21/2020, 08:30 - 08:50,
-
+
Before (Slides Available)
08:30 - 08:40 | Author(s): Valerie Rusch
- Abstract
No abstract available for this presentation
-
+
After (Slides Available)
08:40 - 08:50 | Author(s): Jessica Donington
- Abstract
No abstract available for this presentation
